Stevanato Group S.p.A. (NYSE:STVN) Stock Now Rated “Moderate Buy” by Wall Street Analysts

Stevanato Group S.p.A. (NYSE:STVN) has earned a consensus recommendation of “Moderate Buy” from the eight analysts that are currently covering the stock, Marketbeat Ratings reports. Four analysts have rated the stock with a hold rating, two have assigned a buy rating and two have issued a strong buy rating on the company.

Several research firms recently weighed in on STVN. UBS Group started coverage on shares of Stevanato Group in a research note on Wednesday, September 9th. They set a “neutral” rating and a $23.00 price objective on the stock. Deutsche Bank Aktiengesellschaft started coverage on Stevanato Group in a report on Wednesday, October 7th. They set a “hold” rating for the company. Finally, Weiss Ratings raised Stevanato Group from a “hold (c-)” rating to a “hold (c)” rating in a report on Thursday, August 27th.

Insider Buying and Selling

In other Stevanato Group news, Director Luciano Santel sold 2,023 shares of the stock in a transaction on Friday, August 7th. The stock was sold at an average price of €20.09, for a total value of €40,642.07. Following the sale, the director directly owned 4,739 shares of the company’s stock, valued at €95,206.51. This trade represents a 29.92% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Mauro Stocchi sold 13,649 shares of the stock in a transaction on Monday, September 28th. The stock was sold at an average price of €21.50, for a total value of €293,453.50. Following the completion of the sale, the insider directly owned 400,000 shares in the company, valued at €8,600,000. This represents a 3.30% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders have sold 21,926 shares of company stock worth $459,738.

Hedge Funds Weigh In On Stevanato Group

Several hedge funds and other institutional investors have recently modified their holdings of STVN. State of Wyoming bought a new position in shares of Stevanato Group during the third quarter worth about $75,000. Schwartz Investment Counsel Inc. grew its holdings in Stevanato Group by 15.0% in the 3rd quarter. Schwartz Investment Counsel Inc. now owns 661,136 shares of the company’s stock worth $13,871,000 after buying an additional 86,385 shares in the last quarter. PineStone Asset Management Inc. increased its position in Stevanato Group by 8.4% in the 3rd quarter. PineStone Asset Management Inc. now owns 41,335 shares of the company’s stock valued at $867,000 after acquiring an additional 3,200 shares during the period. Fenimore Asset Management Inc acquired a new stake in Stevanato Group in the 3rd quarter valued at approximately $12,212,000. Finally, Integrated Wealth Concepts LLC acquired a new stake in Stevanato Group in the 2nd quarter valued at approximately $59,000.

Stevanato Group Stock Down 0.4%

STVN stock opened at €19.30 on Monday. The firm has a market cap of $5.84 billion, a price-to-earnings ratio of 34.46, a PEG ratio of 1.59 and a beta of 0.80. Stevanato Group has a 1-year low of €12.89 and a 1-year high of €27.00. The firm has a fifty day moving average price of €20.58 and a two-hundred day moving average price of €18.14. The company has a debt-to-equity ratio of 0.21, a current ratio of 1.61 and a quick ratio of 1.08.

Stevanato Group (NYSE:STVN) last posted its quarterly earnings results on Wednesday, August 5th. The company reported €0.14 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of €0.15 by (€0.01). Stevanato Group had a return on equity of 10.43% and a net margin of 10.99%. The business had revenue of €302.00 million during the quarter. Research analysts predict that Stevanato Group will post 0.69 EPS for the current year.

Stevanato Group Company Profile

Stevanato Group S.p.A. is an Italy-based provider of drug-containment and drug-delivery solutions for the pharmaceutical, biotechnology and healthcare industries. Founded in 1949, the company has developed from a glass-packaging manufacturer into an integrated supplier serving customers throughout the global pharmaceutical supply chain.

The company manufactures primary packaging products, including glass vials, syringes, cartridges and ampoules, as well as components and systems used to contain and administer injectable medicines.